Case Discussions in HSCT - TMA: Integrating New Data to Improve Patient Outcomes

 

This activity can be accessed using the following URL: 

Target Audience

  • Hematologists
  • Medical Oncologists
  • Researchers
  • Investigators who treat or are interested in the treatment of patients with hematologic malignancies
  • Other allied healthcare professionals (Nurse Practitioners, Physician Assistants, and Nurses involved in the treatment and management of patients with hematologic malignancies

Learning Objectives

• Updates on novel induction and integration of targeted agents

• Antibody strategies in HCT-eligible AML: from conditioning to future applications

• Insights on maintenance strategies in HCT recipients

Additional information

Contact

Name: 
Sherry Fisher
Phone Number: 
+1 (414) 805-0687
Email: 
slfisher@mcw.edu
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
02/11/2021
Course expires: 
02/12/2022
Cost:
$0.00

Support Statement
This activity is supported by an educational grant from Actinium Pharmaceuticals, Astellas Pharma Global Development, Inc., Bristol Myers Squibb, and Gilead Sciences, Inc.

 

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multi-step process.

Faculty:

Parameswaran Hari, MD, MRCP
Armand J. Quick/William F. Stapp Professor of Hematology
Chief, Division of Hematology and Oncology
Department of Medicine
Medical College of Wisconsin
Milwaukee, WI

Disclosures: Consulting Honoraria: Bristol Myers Squibb, Takeda, Amgen, Janssen, Karyopharm, Juno, GlaxoSmithKline, AbbVie.

Shaji Kumar, MD
Professor of Medicine
Department of Hematology
Consultant, Division of Hematology
Department of Internal Medicine
Mayo Clinic
Rochester, MN

Disclosures: Grant Research Support: Celgene, Takeda, Janssen, Bristol Myers Squibb, Sanofi, Kite Pharma, Merck, AbbVie, MedImmune, Novartis, Roche-Genentech, Amgen, Tenebrio, Carsgen; Consultant: (with no personal payments) Celgene, Takeda, Janssen, Kite Pharma, Merck, AbbVie, MedImmune, Genentech, Amgen, Molecular Partners and (with personal payment) Oncopeptides, Adaptive, Genecentrix.

The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.


The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

 

 

image
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PER, Physician Education Resource, LLC. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Providership

This CME activity is jointly provided by The Medical College of Wisconsin and PER, Physician Education Resource, LLC.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.